title: Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?
authors.forename: M
authors.initials: M
authors.lastname: Di Maio
authors.forename: E
authors.initials: E
authors.lastname: Bria
authors.forename: A
authors.initials: A
authors.lastname: Rossi
authors.forename: F
authors.initials: F
authors.lastname: Perrone
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D010166:Palliative Care; D011013:Pneumonectomy; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D016190:Carboplatin; D017239:Paclitaxel